July 2nd 2022
The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.
June 17th 2022
The therapy is now being evaluated in a phase 2 study.
June 16th 2022
CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).
Mustang Bio presented data on MB-106 at the 2022 EHA Congress.
June 15th 2022
Among treated patients, 42% achieved 5-year event free survival.
June 13th 2022
GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.
The CD-19 CAR T-cell therapy is developed using Curocell’s OVISTM platform.
Results from the CLIMB THAL-111 and CLIMB SCD-121 trials were presented at the EHA 2022 Congress.
June 12th 2022
Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.
Participants in the trial achieved a sustained response and experienced low-grade toxicity.